BioSpace News Archive

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2020.

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced that it will host a conference call on Monday, August 10, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2020, and recent operational highlights.

Aduro Biotech, Inc., a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand and Stimulator of Interferon Genes pathways for the treatment of cancer, autoimmune and inflammatory diseases, provided a business update and reported financial results for the second quarter ended June 30, 2020.

Salarius Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $1.20 per share.

Pacific Biosciences of California, Inc. announced financial results for its second quarter ended June 30, 2020.

Surgalign Holdings, Inc. announced that it is changing its earnings release and conference call date for the second quarter 2020 as a result of a delay completing the financial statements due to the additional workload created by the recently completed sale of the OEM business.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Monday, August 10, and will host a corporate update conference call at 4:30pm Eastern Time.

CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter and six months ended June 30, 2020 and to provide a business update.

Achieve Life Sciences, Inc. announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, to certain investors whose purchase of common stock would result in the investor, together with its affiliates, beneficially owning more than 9.99% of Achieve’s common stock following the completion of the offering, pre-funded warrants to purchase shares of common stock.

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $268 million with Approximately 46,400 TRx